[Methotrexate for therapy of rheumatoid arthritis].
Suzuki
Yasuo
Y
Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine.
Wakabayashi
Takayuki
T
Jackson
Kanako
K
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D018501:Antirheumatic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D000068800:Etanercept; D019317:Evidence-Based Medicine; D005492:Folic Acid / Q000008:administration & dosage; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage; D000069285:Infliximab; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D005492:Folic Acid; D000069285:Infliximab; D000068800:Etanercept; D008727:Methotrexate